Literature DB >> 15160833

Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.

Kirkwood F Adams1.   

Abstract

PURPOSE: The pathophysiology of heart failure is reviewed, with particular focus on the role of abnormal neurohormonal activation of the sympathetic nervous system and the renin-angiotensin-aldosterone axis in the pathophysiology of this syndrome.
SUMMARY: Events preceding myocardial infarction and heart failure are driven in part by norepinephrine, angiotensin II, and aldosterone. The sympathetic nervous system likely evolved to mediate acute regulation of the cardiovascular system, not the sustained activation that is seen in heart failure. Overexpression of beta1-receptors in animal models results in decreased left ventricular ejection fraction and ventricular remodeling. In patients with systolic dysfunction, beta-blockade has improved left ventricular function and decreased the risk of sudden death. Chronic exposure to excess angiotensin II produces eccentric ventricular hypertrophy, vasoconstriction, and sodium retention. Angiotensin-converting enzyme (ACE) inhibition causes only a transient depression of aldosterone concentrations; the chronic benefit from ACE inhibition in patients with heart failure likely results from augmentation of bradykinin and not from the inhibition of angiotensin II production. Administration of eplerenone, a selective mineralocorticoid receptor antagonist, following induction of ischemic injury in animals, blocked the progressive ventricular dilatation and reduction in systolic function observed in control animals; clinical studies indicate that those findings can be translated to human cardiovascular disease. Overactivity of the mineralocorticoid receptor in cardiomyocytes could be important even in the absence of excessive levels of aldosterone. Clinical studies demonstrated that strategies of neurohormonal blockade using an ACE inhibitor, angiotensin II receptor antagonist, and beta-blocker are ineffective in reducing circulating aldosterone in patients with heart failure caused by left ventricular systolic dysfunction.
CONCLUSION: Aldosterone is a key deleterious hormone influencing all forms of cardiovascular disease, including hypertension, myocardial infarction, and heart failure. Treatment of many cardiovascular diseases should include specific antagonism of the adverse pathophysiologic consequences of aldosterone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15160833     DOI: 10.1093/ajhp/61.suppl_2.S4

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  16 in total

Review 1.  Cytoskeletal regulation of TRPC channels in the cardiorenal system.

Authors:  Jonathan A Stiber; Youlan Tang; TianYu Li; Paul B Rosenberg
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

Review 2.  Progress toward genetic tailoring of heart failure therapy.

Authors:  John H Lillvis; David E Lanfear
Journal:  Curr Opin Mol Ther       Date:  2010-06

Review 3.  The relationship of stress and blood pressure effectors.

Authors:  C Ayada; Ü Toru; Y Korkut
Journal:  Hippokratia       Date:  2015 Apr-Jun       Impact factor: 0.471

Review 4.  Candesartan cilexetil: a review of its use in the management of chronic heart failure.

Authors:  Caroline Fenton; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Hyperosmotic activation of CNS sympathetic drive: implications for cardiovascular disease.

Authors:  Glenn M Toney; Sean D Stocker
Journal:  J Physiol       Date:  2010-07-05       Impact factor: 5.182

6.  Measures of body composition and risk of heart failure in the elderly: the Rotterdam study.

Authors:  M A W Van Lieshout; G C Verwoert; F U S Mattace-Raso; M C Zillikens; E J Sijbrands; J W Deckers; A Hofman; J C M Witteman
Journal:  J Nutr Health Aging       Date:  2011-05       Impact factor: 4.075

7.  Neuroendocrine profile in a rat model of psychosocial stress: relation to oxidative stress.

Authors:  Marilena Colaianna; Stefania Schiavone; Margherita Zotti; Paolo Tucci; Maria Grazia Morgese; Liselotte Bäckdahl; Rikard Holmdahl; Karl-Heinz Krause; Vincenzo Cuomo; Luigia Trabace
Journal:  Antioxid Redox Signal       Date:  2013-04-20       Impact factor: 8.401

Review 8.  Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies.

Authors:  John W Wright; Shigehiko Mizutani; Joseph W Harding
Journal:  Heart Fail Rev       Date:  2007-11-07       Impact factor: 4.214

Review 9.  Left atrial remodelling contributes to the progression of asymptomatic left ventricular systolic dysfunction to chronic symptomatic heart failure.

Authors:  George Karayannis; George Kitsios; Haralambos Kotidis; Filippos Triposkiadis
Journal:  Heart Fail Rev       Date:  2007-04-21       Impact factor: 4.214

10.  Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension.

Authors:  John W Wright; Shigehiko Mizutani; Joseph W Harding
Journal:  Int J Hypertens       Date:  2012-06-26       Impact factor: 2.420

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.